EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	16	"6268391"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 10:25
L2	3	"7084147"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 10:27
L3	5	"6719339"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 10:27
L4	3	"7109333"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 10:50
L5	9	"6727256"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 14:04
L6	2	"7189734"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 10:50
L7	2	"7141576"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 11:11
L8	12	"6713485"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 11:11

EAST Search History

L9	7	"bRaf inhibitor"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 14:38
L10	64	"Raf inhibitor"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 14:38
L11	55	"Raf inhibitor" and "cancer"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 14:40
L12	10	"b-Raf inhibitor" and "cancer"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:33
L13	0	514/264.110	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:34
L14	0	514/264.110.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:34
L15	0	514/264.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:34
L16	166	514/264.11.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:34

EAST Search History

L17	22	514/264.11.ccls. and ("erbb2" or "raf")	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:35

- Search History will be lost after eight hours of inactivity.
- Search numbers may not be continuous; all searches are represented.
- To save search indefinitely, click query # and select Save in My NCBI.
- To combine searches use #search, e.g., #2 AND #3 or click query # for more options.

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorials
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Search	Most Recent Queries	Time	Result
#18	Search **b-raf and cancer**	14:42:48	560
#17	Search **b-raf or braf and cancer**	14:42:25	1009
#16	Search **b-raf or braf**	14:42:18	1130
#15	Search **CFPAC-1**	12:32:35	97
#13	Search **ERBb2 and leukemia**	12:15:08	78
#12	Search **ERBb2 and cRaf-1**	12:14:39	1
#11	Search **ERBb2 and cRaf-1 inhibitor**	12:14:35	0
#9	Search **ERBb2 and Raf inhibitors**	12:14:07	62
#8	Search **ERBb2 and Raf**	12:12:56	111
#1	Search **GW572016**	12:10:04	28

Clear History

10/510,542
4/16/07

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 4	DEC 18	CA/CAplus patent kind codes updated
NEWS 5	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 6	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 7	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 8	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 10	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 11	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 13	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 14	JAN 29	PHAR reloaded with new search and display fields
NEWS 15	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 17	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 18	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19	FEB 26	MEDLINE reloaded with enhancements
NEWS 20	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 21	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 22	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 24	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25	MAR 16	CASREACT coverage extended
NEWS 26	MAR 20	MARPAT now updated daily
NEWS 27	MAR 22	LWPI reloaded
NEWS 28	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 29	MAR 30	INPADOCDB will replace INPADOC on STN
NEWS 30	APR 02	JICST-EPLUS removed from database clusters and STN

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:10:44 ON 13 APR 2007

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:10:57 ON 13 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 APR 2007 HIGHEST RN 929960-62-3
DICTIONARY FILE UPDATES: 12 APR 2007 HIGHEST RN 929960-62-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10510542_specie.str



chain nodes :
11 18 19 20 27 33 34 35 36 37 38
ring nodes :

```
1  2  3  4  5  6  7  8  9  10  12  13  14  15  16  17  21  22  23  24  25  26  28
29  30  31  32
chain bonds :
3-28  7-11  11-12  15-19  16-18  19-20  20-21  25-27  30-33  33-34  34-35  35-36
36-37  37-38
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10  12-13  12-17  13-14  14-15
15-16  16-17  21-22  21-26  22-23  23-24  24-25  25-26  28-29  28-32  29-30  30-31
31-32
exact/norm bonds :
7-11  11-12  15-19  28-29  28-32  29-30  30-31  31-32
exact bonds :
3-28  16-18  19-20  20-21  25-27  30-33  33-34  34-35  35-36  36-37  37-38
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10  12-13  12-17  13-14  14-15
15-16  16-17  21-22  21-26  22-23  23-24  24-25  25-26

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:CLASS  19:CLASS
20:CLASS  21:Atom
22:Atom  23:Atom  24:Atom  25:Atom  26:Atom  27:CLASS  28:Atom  29:Atom  30:Atom
31:Atom  32:Atom
33:CLASS  34:CLASS  35:CLASS  36:CLASS  37:CLASS  38:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l1 full
FULL SEARCH INITIATED 16:11:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       93 TO ITERATE

100.0% PROCESSED       93 ITERATIONS                                12 ANSWERS
SEARCH TIME: 00.00.01

L2           12 SEA SSS FUL L1

=> s l1 exa full
FULL SEARCH INITIATED 16:11:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       25 TO ITERATE

100.0% PROCESSED       25 ITERATIONS                                 1 ANSWERS
SEARCH TIME: 00.00.01

L3            1 SEA EXA FUL L1

=> d l3

L3   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
```

RN 231277-92-2 REGISTRY
ED Entered STN: 07 Aug 1999
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)
OTHER NAMES:
CN 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
CN GW 572016
CN Lapatinib
MF C29 H26 Cl F N4 O4 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

135 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
136 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline caplus wpids uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	232.30	232.51

FILE 'MEDLINE' ENTERED AT 16:11:56 ON 13 APR 2007

FILE 'CAPLUS' ENTERED AT 16:11:56 ON 13 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'WPIDS' ENTERED AT 16:11:56 ON 13 APR 2007

FILE 'USPATFULL' ENTERED AT 16:11:56 ON 13 APR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l3
SAMPLE SEARCH INITIATED 16:12:01 FILE 'WPIDS'
SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3 TO 81
PROJECTED ANSWERS: 1 TO 40

L4 180 L3

=> s l3 not py>2003
COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID
The query entered contains both search terms created by
structure-building or screen commands and text search terms. L#s
created via the STRUCTURE or SCREEN commands must be searched in the
structures files separately from text terms or profiles. The L#
answer sets from structure searches can be used in crossover searches
and can be combined with text terms.

=> s l4 not py>2003
L5 7 L4 NOT PY>2003

=> d l5 1-7 ibib, abs, hitstr

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:917646 CAPLUS Full-text
DOCUMENT NUMBER: 140:38051
TITLE: Epidermal Growth Factor Receptor Autocrine Signaling in RIE-1 Cells Transformed by the Ras Oncogene Enhances Radiation Resistance
AUTHOR(S): Grana, Theresa M.; Sartor, Carolyn I.; Cox, Adrienne D.
CORPORATE SOURCE: Curriculum in Genetics and Molecular Biology, Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC, USA
SOURCE: Cancer Research (2003), 63(22), 7807-7814
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Oncogenic forms of the small GTPase Ras increase the resistance of cells to killing by ionizing radiation (IR). Although not all of the signaling pathways for radioresistance are well defined, it is now clear that Ras-dependent signaling pathways involved in radioresistance include those mediated by phosphatidylinositol 3'-kinase (PI3-K) and Raf. Nevertheless, PI3-K and Raf together are not sufficient to reconstitute all of the resistance conferred by Ras, indicating that other effectors must also contribute. We show here that Ras-driven autocrine signaling through the epidermal growth factor receptor (EGFR) also contributes to radioresistance in Ras-transformed cells. Conditioned media (CM) collected from RIE-1 rat intestinal epithelial cells expressing oncogenic Ras increased the survival of irradiated cells. Ras-CM contains elevated levels of the EGFR ligand

transforming growth factor α (TGF-α). Both Ras-CM and TGF-α stimulated EGFR phosphorylation, and exogenous TGF-α mimicked the effects of Ras-CM to increase radioresistance. Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI) GW572016 decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells. Ras-CM and TGF-α also increase PI3-K activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by GW572016. Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI GW572016 acts as a radiosensitizer. The observation that Ras-transformed cells can be sensitized to killing by ionizing radiation with GW572016 demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR.

IT 231277-92-2, GW572016
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ras utilizes autocrine signaling through EGF receptor to increase radioresistance in Ras-transformed cells and GW572016 acts as a radiosensitizer)

RN 231277-92-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



REFERENCE COUNT: 83 THERE ARE 83 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:8967 CAPLUS Full-text

DOCUMENT NUMBER: 139:62338

TITLE: Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents

AUTHOR(S): Laird, A. Douglas; Cherrington, Julie M.

CORPORATE SOURCE: SUGEN, Inc., South San Francisco, CA, 94080, USA

SOURCE: Expert Opinion on Investigational Drugs (2003), 12(1), 51-64
CODEN: EOIDER; ISSN: 1354-3784

PUBLISHER: Ashley Publications Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Numerous small mol. synthetic tyrosine kinase inhibitors are in clin. development for the treatment of human cancers. These fall into three

broad categories: inhibitors of the epidermal growth factor receptor tyrosine kinase family (e.g., Iressa and Tarceva), inhibitors of the split kinase domain receptor tyrosine kinase subgroup (e.g., PTK787/ZK 222584 and SU11248) and inhibitors of tyrosine kinases from multiple subgroups (e.g., Gleevec). In addition, agents targeting other tyrosine kinases implicated in cancer, such as Met, Tie-2 and Src, are in preclin. development. As experience is gained in the clinic, it has become clear that unleashing the full therapeutic potential of tyrosine kinase inhibitors will require patient preselection, better assays to guide dose selection, knowledge of mechanism-based side effects and ways to predict and overcome drug resistance.

IT 231277-92-2, GW-572016
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(small mol. tyrosine kinase inhibitors and clin. development of anticancer agents)

RN 231277-92-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



REFERENCE COUNT: 127 THERE ARE 127 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

NOT PRIOR ART

ACCESSION NUMBER: 2002:668812 CAPLUS Full-text
DOCUMENT NUMBER: 138:280796
TITLE: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
AUTHOR(S): Xia, Wenle; Mullin, Robert J.; Keith, Barry R.; Liu, Lei-Hua; Ma, Hong; Rusnak, David W.; Owens, Gary; Alligood, Krystal J.; Spector, Neil L.
CORPORATE SOURCE: GlaxoSmithKline, Department of Discovery Medicine, Research Triangle Park, North Carolina, NC, 27709-3398, USA
SOURCE: Oncogene (2002), 21(41), 6255-6263
CODEN: ONCNES; ISSN: 0950-9232
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR heterodimerization triggers potent proliferative and survival signals. Here we show that a small mol., GW572016, potently inhibits both EGFR and erbB2 tyrosine kinases leading to growth arrest and/or apoptosis in EGFR and erbB2-dependent tumor cell lines. GW572016 markedly reduced tyrosine phosphorylation of EGFR and erbB2, and inhibited activation of Erk1/2 and AKT, downstream effectors of proliferation and cell survival, resp. Complete inhibition of activated AKT in erbB2 overexpressing cells correlated with a 23-fold increase in apoptosis compared with vehicle controls. EGF, often elevated in cancer patients, did not reverse the inhibitory effects of GW572016. These observations were reproduced in vivo, where GW572016 treatment inhibited activation of EGFR, erbB2, Erk1/2 and AKT in human tumor xenografts. Erk1/2 and AKT represent potential biomarkers to assess the clin. activity of GW572016. Inhibition of activated AKT in EGFR or erbB2-dependent tumors by GW572016 may lead to tumor regressions when used as a monotherapy, or may enhance the anti-tumor activity of chemotherapeutics, since constitutive activation of AKT has been linked to chemo-resistance.

IT 231277-92-2, GW 572016
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GW572016 antitumor activity: dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways)

RN 231277-92-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 7 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L5 ANSWER 5 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2003:319330 USPATFULL Full-text

TITLE: Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy

INVENTOR(S): Singer, Thomas, Inzlingen, GERMANY, FEDERAL REPUBLIC OF
Platz, Stefan, Ummendorf, GERMANY, FEDERAL REPUBLIC OF

Colbatzky, Florian, Stafflangen, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & CO. KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003225079	A1	20031204
APPLICATION INFO.:	US 2003-431699	A1	20030508 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10221018	20020511
	US 2002-389815P	20020618 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 896
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 231277-92-2
(EGFR-mediated signal transduction inhibitors for treatment of benign prostatic hyperplasia/prostatic hypertrophy)

RN 231277-92-2 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



L5 ANSWER 6 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2003:251662 USPATFULL Full-text
TITLE: Heterocyclic compounds
INVENTOR(S): Carter, Malcolm Clive, Ware, UNITED KINGDOM
Cockerill, George Stuart, Bedford, UNITED KINGDOM
Guntrip, Stephen Barry, Hertford, UNITED KINGDOM
Lackey, Karen Elizabeth, Hillsborough, NC, UNITED STATES
Smith, Kathryn Jane, Bishop's Stortford, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003176451	A1	20030918
APPLICATION INFO.:	US 2003-342810	A1	20030115 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-582746, filed on 30 Jun 2000, PENDING A 371 of International Ser. No. WO 1999-EP48, filed on 8 Jan 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-569	19980112

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 3892
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for the preparation of a compound of formula (I) ##STR1##

comprising the steps:

(a) reacting a compound of formula (II) ##STR2##

wherein L and L' are suitable leaving groups, with a compound of formula (III)

UNH.sub.2 (III)

to prepare a compound of formula (IV) ##STR3##

and subsequently (b) substituting the group R.sup.1 by replacement of the leaving group L'.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 231277-92-2P
(target compound; preparation of quinazolinamines and analogs as protein tyrosine kinase inhibitors)
RN 231277-92-2 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



L5 ANSWER 7 OF 7 USPATFULL on STN

ACCESSION NUMBER:	2003:214419 USPATFULL Full-text
TITLE:	Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
INVENTOR(S):	Jung, Birgit, Laupheim, GERMANY, FEDERAL REPUBLIC OF Pueschner, Hubert, Biberach, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S):	Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003149062	A1	20030807
APPLICATION INFO.:	US 2003-353616	A1	20030129 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10204462	20020205

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS:	8
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	2 Drawing Page(s)
LINE COUNT:	1686

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating inflammatory diseases of the airways or intestines which comprises administering substances selected from the group consisting of:

(a) quinazolines of general formula ##STR1##

wherein A, B, C, D, X, R.sup.a, R.sup.b, R.sup.c and n are as defined herein,

(b) the compounds

(1) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-dimethylamino-cyclohexyl)amino]-pyrimido[5,4-d]pyrimidine,

(2) 4-[(R)-(1-phenylethyl)amino]-6-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine, and

(3) 4-{[3-chloro-4-(3-fluoro-4-benzyloxy)-phenyl]amino}-6-(5-{[(2-methanesulphonyl-ethyl)amino]methyl}-furan-2-yl)quinazoline or

(d) the antibodies Cetuximab C225, Trastuzumab, ABX-EGF and Mab ICR-62, and

(f) EGFR-antisense.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 231277-92-2
(tyrosine kinase inhibitors for treatment of pulmonary inflammatory conditions)
RN 231277-92-2 USPATFULL
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	44.42	276.93

```
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                  -2.34      -2.34

FILE 'STNGUIDE' ENTERED AT 16:13:21 ON 13 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr  6, 2007 (20070406/UP).

=> d his

     (FILE 'HOME' ENTERED AT 16:10:44 ON 13 APR 2007)

     FILE 'REGISTRY' ENTERED AT 16:10:57 ON 13 APR 2007
L1               STRUCTURE UPLOADED
L2            12 S L1 FULL
L3             1 S L1 EXA FULL

     FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 16:11:56 ON 13 APR
     2007
L4           180 S L3
L5             7 S L4 NOT PY>2003

     FILE 'STNGUIDE' ENTERED AT 16:13:21 ON 13 APR 2007

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   0.24     277.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                   0.00      -2.34

STN INTERNATIONAL LOGOFF AT 16:15:31 ON 13 APR 2007
```

10/510,542
4/16/07

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:16:10 ON 13 APR 2007

=> **file registry**

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:16:38 ON 13 APR 2007

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 APR 2007 HIGHEST RN 929960-62-3
DICTIONARY FILE UPDATES: 12 APR 2007 HIGHEST RN 929960-62-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10510542_specie.str



chain nodes :
11 18 19 20 27 33 34 35 36 37 38
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 21 22 23 24 25 26 28 29 30 31 32
chain bonds :
3-28 7-11 11-12 15-19 16-18 19-20 20-21 25-27 30-33 33-34 34-35 35-36 36-37 37-38
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15 15-16 16-17 21-22 21-26 22-23 23-24 24-25 25-26 28-29 28-32 29-30 30-31 31-32
exact/norm bonds :

```
7-11  11-12  15-19  28-29  28-32  29-30  30-31  31-32
exact bonds :
3-28  16-18  19-20  20-21  25-27  30-33  33-34  34-35  35-36  36-37  37-38
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10  12-13  12-17  13-14  14-15
15-16  16-17  21-22  21-26  22-23  23-24  24-25  25-26


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:CLASS  19:CLASS
20:CLASS  21:Atom
22:Atom  23:Atom  24:Atom  25:Atom  26:Atom  27:CLASS  28:Atom  29:Atom  30:Atom
31:Atom  32:Atom
33:CLASS  34:CLASS  35:CLASS  36:CLASS  37:CLASS  38:CLASS



L1      STRUCTURE UPLOADED

=> s l1 exa full
FULL SEARCH INITIATED 16:17:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       25 TO ITERATE

100.0% PROCESSED      25 ITERATIONS                                  1 ANSWERS
SEARCH TIME: 00.00.01

L2            1 SEA EXA FUL L1

=> d l2

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   231277-92-2  REGISTRY
ED   Entered STN:  07 Aug 1999
CN   4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-
     [[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-  (CA INDEX NAME)
OTHER NAMES:
CN   4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-
     methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
CN   GW 572016
CN   Lapatinib
MF   C29 H26 Cl F N4 O4 S
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CBNB,
       CHEMCATS, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, PROUSDDR,
       SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

135 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
136 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> **file uspatfull**

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	60.20	60.41

FILE 'USPATFULL' ENTERED AT 16:17:17 ON 13 APR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 12 Apr 2007 (20070412/PD)
FILE LAST UPDATED: 12 Apr 2007 (20070412/ED)
HIGHEST GRANTED PATENT NUMBER: US7203969
HIGHEST APPLICATION PUBLICATION NUMBER: US2007083964
CA INDEXING IS CURRENT THROUGH 12 Apr 2007 (20070412/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 12 Apr 2007 (20070412/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2006

=> **s l2**
L3 43 L2

=> s l3 and Raf
5746 RAF
L4 10 L3 AND RAF

=> **d l4 1-10 ibib, abs**

L4 ANSWER 1 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2007:11185 USPATFULL Full-text
TITLE: Methods of treating cancer
INVENTOR(S): Potter, David A., Indianapolis, IN, UNITED STATES
PATENT ASSIGNEE(S): Indianan University Advanced Research (U.S. corporation)

Technology Institute, a Indiana corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007009593	A1	20070111
APPLICATION INFO.:	US 2006-451875	A1	20060613 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2003-629045, filed on 28 Jul 2003, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-399573P	20020726 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, P.O. BOX 1022, MINNEAPOLIS, MN, 55440-1022, US
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 1506
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating cancer are described herein. The methods include administering to an HIV-negative patient an m-calpain inhibitor such as ritonavir. Ritonavir or other m-calpain inhibitors can also be co-administered with other therapeutic agents such as a Cox-2 inhibitor, a taxane, or a proteasome inhibitor. Methods for determining whether a patient will respond to a particular method of treatment are also described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2006:253838 USPATFULL Full-text
TITLE: Combinations for the treatment of cancer
INVENTOR(S): Chang, David, Calabasas, CA, UNITED STATES
PATENT ASSIGNEE(S): Amgen Inc, Thousand Oaks, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006216288	A1	20060928
APPLICATION INFO.:	US 2006-386271	A1	20060321 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-664381P	20050322 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AMGEN INC., MAIL STOP 28-2-C, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799, US
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2006:208454 USPATFULL Full-text
TITLE: Inhibiting HER2 shedding with matrix metalloprotease antagonists
INVENTOR(S): Carey, Kendall D., South San Francisco, CA, UNITED STATES
Schwall, Ralph, Pacifica, CA, UNITED STATES
Sliwkowski, Mark, San Carlos, CA, UNITED STATES
Schwall, Gail Colbern, Pacifica, CA, UNITED STATES legal representative
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006177448	A1	20060810
APPLICATION INFO.:	US 2006-351811	A1	20060209 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-651348P	20050209 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 3198
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present application describes using antagonists of matrix metalloproteases (MMPs), especially of MMP-15, for inhibiting HER2 shedding.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2006:131781 USPATFULL Full-text
TITLE: Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease
INVENTOR(S): Zeligs, Michael A., Boulder, CO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006111423	A1	20060525
APPLICATION INFO.:	US 2005-260543	A1	20051026 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-622333P	20041026 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 2738
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes compositions and methods for the treatment and prevention of conditions associated with Human Cytomegalovirus (HCMV) infection. HCMV-associated conditions include infections (active and latent), benign cell-proliferative conditions, pre-cancerous cell-proliferative conditions, and cancerous conditions. In particular, the present invention describes new therapeutic and preventative uses for 3,3'-diindolylmethane (DIM), or a DIM-related indole, in combination with an inhibitor of a membrane bound Growth Factor Receptor (GFR), to treat conditions associated with exposure to HCMV. In certain embodiments, the compositions of the invention can be used in combination with radiation therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 10 USPATFULL on STN

ACCESSION NUMBER:	2005:261902 USPATFULL Full-text			
TITLE:	Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent			
INVENTOR(S):	Masferrer, Jaime L., Ballwin, MO, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005227929	A1	20051013	
APPLICATION INFO.:	US 2004-989192	A1	20041115	(10)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2003-519701P		20031113	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	Harness, Dickey & Pierce, P.L.C., Suite 400, 7700 Bonhomme, St. Louis, MO, 63105, US			
NUMBER OF CLAIMS:	20			
EXEMPLARY CLAIM:	1			
LINE COUNT:	12553			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treating or preventing neoplasia or a neoplasia-related disorder in a subject is provided, the method comprising administering to the subject an effective amount of a combination comprising a Cox-2 inhibitor and an antineoplastic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 10 USPATFULL on STN

ACCESSION NUMBER:	2005:255665 USPATFULL Full-text			
TITLE:	Combinations of signal transduction inhibitors			
INVENTOR(S):	Eck, Stephen Louis, Ann Arbor, MI, UNITED STATES Fry, David William, Ypsilanti, MI, UNITED STATES Leopold, Judith Ann, Ann Arbor, MI, UNITED STATES			
PATENT ASSIGNEE(S):	PFIZER INC (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005222163	A1	20051006	
APPLICATION INFO.:	US 2005-95442	A1	20050330	(11)
	NUMBER		DATE	

PRIORITY INFORMATION: US 2004-557623P 20040330 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AGOURON PHARMACEUTICALS, INC., 10777 SCIENCE CENTER DRIVE, SAN DIEGO, CA, 92121, US
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 3071
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for treating cancer comprising utilizing a combination of signal transduction inhibitors. More specifically, the present invention relates to combinations of so called cell cycle inhibitors with mitogen stimulated kinase signal transduction inhibitors, more specifically combinations of CDK inhibitors with mitogen stimulated kinase signal transduction inhibitors, more preferably MEK inhibitors. Other embodiments of the invention relate to additional combinations of the aforesaid combinations with standard anti-cancer agents such as cytotoxic agents, palliatives and antiangiogenics. Most specifically this invention relates to combinations of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl- pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one including salt forms, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor, in combination with one or more MEK inhibitors, most preferably N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide. The aforementioned combinations are useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

APPLICATION

L4 ANSWER 7 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2005:203315 USPATFULL Full-text
TITLE: Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
INVENTOR(S): Spector, Neil Lee, Durham, NC, UNITED STATES
Xia, Wenle, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005176740	A1	20050811	
APPLICATION INFO.:	US 2003-510542	A1	20030408	(10)
	WO 2003-US10747		20030408	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-370807P	20020408 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 3918
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an

erb family inhibitor and a Raf and/or ras inhibitor to a mammal suffering from a cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2005:157855 USPATFULL Full-text
TITLE: Anti-IGFR antibody therapeutic combinations
INVENTOR(S): Wang, Yan, Scotch Plains, NJ, UNITED STATES
Pachter, Jonathan A., Chatham, NJ, UNITED STATES
Bishop, Walter Robert, Pompton Plains, NJ, UNITED STATES
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005136063	A1	20050623
APPLICATION INFO.:	US 2004-993395	A1	20041119 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-524732P	20031121 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 2883
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides combinations including a binding composition, such as an anti-IGFR1 antibody, in association with a chemotherapeutic agent. Methods for using the combinations to treat medical conditions, such as cancer, are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2004:216030 USPATFULL Full-text
TITLE: Methods of treating cancer
INVENTOR(S): Potter, David A., Indianapolis, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004167139	A1	20040826
APPLICATION INFO.:	US 2003-629045	A1	20030728 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-399573P	20020726 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)

LINE COUNT: 1653
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for treating cancer are described herein. The methods include administering to an HIV-negative patient an m-calpain inhibitor such as ritonavir. Ritonavir or other m-calpain inhibitors can also be co-administered with other therapeutic agents such as a Cox-2 inhibitor, a taxane, or a proteasome inhibitor. Methods for determining whether a patient will respond to a particular method of treatment are also described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 10 USPATFULL on STN

ACCESSION NUMBER:	2004:70718 USPATFULL Full-text			
TITLE:	Cancer treatment method			
INVENTOR(S):	Lackey, Karen Elizabeth, Durham, NC, UNITED STATES Spector, Neil, Durham, NC, UNITED STATES Wood III, Edgar Raymond, Durham, NC, UNITED STATES Xia, Wenle, Durham, NC, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004053946	A1	20040318	
	US 7141576	B2	20061128	
APPLICATION INFO.:	US 2003-466290	A1	20030715	(10)
	WO -US201130			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398			
NUMBER OF CLAIMS:	27			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	3 Drawing Page(s)			
LINE COUNT:	1780			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> **d his**

(FILE 'HOME' ENTERED AT 16:16:10 ON 13 APR 2007)

FILE 'REGISTRY' ENTERED AT 16:16:38 ON 13 APR 2007
L1 STRUCTURE UPLOADED
L2 1 S L1 EXA FULL

FILE 'USPATFULL' ENTERED AT 16:17:17 ON 13 APR 2007
L3 43 S L2
L4 10 S L3 AND RAF

=> **d l3 1-43 ibib, abs**

L3 ANSWER 1 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2007:68538 USPATFULL Full-text

TITLE: Biomarkers in cancer
INVENTOR(S): Bacus, Sarah S., Hinsdale, IL, UNITED STATES
Spector, Neil Lee, Durham, NC, UNITED STATES
PATENT ASSIGNEE(S): SMITHKLINE BEECHAM CORPORATION, Philadelphia, PA, UNITED STATES, 19101 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2007059785	A1	20070315	
APPLICATION INFO.:	US 2004-568251	A1	20040810	(10)
	WO 2004-US26434		20040810	
			20060214	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-495325P	20030815 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1555
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Biomarkers may be used in the treatment of cancer, and as an aid in clinical decision making regarding which anti-cancer therapy to use in a particular patient. Described herein are methods of assessing whether a subject with a solid tumor is suitable for treatment with a dual EGFR/erbB2 tyrosine kinase inhibitor, by assessing the relative localization of pERK or pAKT in tumor cells, and/or assessing pre-treatment tumor cell levels of ErbB2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2007:43082 USPATFULL Full-text
TITLE: Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
INVENTOR(S): KONETZKI, Ingo, Warthausen, GERMANY, FEDERAL REPUBLIC OF
BOUYSSOU, Thierry, Birkenhard, GERMANY, FEDERAL REPUBLIC OF
PESTEL, Sabine, Attenweiler, GERMANY, FEDERAL REPUBLIC OF
SCHNAPP, Andreas, Biberach, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2007037781	A1	20070215	
APPLICATION INFO.:	US 2006-424558	A1	20060616	(11)

	NUMBER	DATE

PRIORITY INFORMATION: DE 2005-102005030733200507O1
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
LINE COUNT: 4559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are medicament combinations which contain in addition to one or more, preferably one, compound of general formula 1 ##STR1## wherein the groups X, R.sup.a, R.sup.b, R.sup.1, R.sup.1', R.sup.2, R.sup.2', R.sup.2", R.sup.2'", V and n may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2007:18058 USPATFULL Full-text
TITLE: HETEROCYCLIC COMPOUNDS
INVENTOR(S): Carter, Malcom Clive, Ware, UNITED KINGDOM
Cockerill, George Stuart, Bedford, UNITED KINGDOM
Guntrip, Stephen Barry, Hertford, UNITED KINGDOM
Lackey, Karen Elizabeth, Hillsborough, NC, UNITED STATES
Smith, Kathryn Jane, Hertfordshire, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007015775	A1	20070118
APPLICATION INFO.:	US 2006-532926	A1	20060919 (11)

CMPD. CLAIM

RELATED APPLN. INFO.: Continuation of Ser. No. US 2005-50033, filed on 3 Feb 2005, GRANTED, Pat. No. US 7109333 Continuation of Ser. No. US 2003-342810, filed on 15 Jan 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-569	19980112
	WO 1999-EP48	19990108

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 3572
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for the preparation of a compound of formula (I) ##STR1## comprising the steps: (a) reacting a compound of formula (II) ##STR2## wherein L and L' are suitable leaving groups, with a compound of formula (III) UNH.sub.2 (III) to prepare a compound of formula (IV) ##STR3##

and subsequently (b) substituting the group R.sup.1 by replacement of the leaving group L'.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2007:17079 USPATFULL Full-text
TITLE: EGFR inhibitors promote axon regeneration
INVENTOR(S): He, Zhigang, Boston, MA, UNITED STATES
Koprivica, Vuk, Boston, MA, UNITED STATES
PATENT ASSIGNEE(S): Children's Medical Center Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007014792	A1	20070118
APPLICATION INFO.:	US 2005-180070	A1	20050712 (11)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: RICHARD ARON OSMAN, SCIENCE AND TECHNOLOGY LAW GROUP, 242 AVE VISTA DEL OCEANO, SAN CLEMEMTE, CA, 92672, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 761
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for promoting neural regeneration in a patient determined to have a lesion in a mature CNS neuron are disclosed. The method comprises the step of contacting the neuron with an EGFR inhibitor sufficient to promote regeneration of the neuron.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2007:11185 USPATFULL Full-text
TITLE: Methods of treating cancer
INVENTOR(S): Potter, David A., Indianapolis, IN, UNITED STATES
PATENT ASSIGNEE(S): Indianan University Advanced Research (U.S. corporation)
Technology Institute, a Indiana corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007009593	A1	20070111
APPLICATION INFO.:	US 2006-451875	A1	20060613 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2003-629045, filed on 28 Jul 2003, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-399573P	20020726 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, P.O. BOX 1022, MINNEAPOLIS, MN, 55440-1022, US
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 1506
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating cancer are described herein. The methods include administering to an HIV-negative patient an m-calpain inhibitor such as ritonavir. Ritonavir or other m-calpain inhibitors can also be co-administered with other therapeutic agents such as a Cox-2 inhibitor, a taxane, or a proteasome inhibitor. Methods for determining whether a patient will respond to a particular method of treatment are also described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 43 USPATFULL on STN NOT PRIOR ART

ACCESSION NUMBER:	2006:307823 USPATFULL Full-text
TITLE:	Combinations and modes of administration of therapeutic agents and combination therapy
INVENTOR(S):	Desai, Neil P., Santa Monica, CA, UNITED STATES Soon-Shiong, Patrick, Los Angeles, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006263434	A1	20061123	
APPLICATION INFO.:	US 2006-359286	A1	20060221	(11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-654245P	20050218 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018, US
NUMBER OF CLAIMS:	49
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	9 Drawing Page(s)
LINE COUNT:	4403

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 43 USPATFULL on STN NOT PRIOR ART

ACCESSION NUMBER:	2006:253838 USPATFULL Full-text
TITLE:	Combinations for the treatment of cancer
INVENTOR(S):	Chang, David, Calabasas, CA, UNITED STATES
PATENT ASSIGNEE(S):	Amgen Inc, Thousand Oaks, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006216288	A1	20060928	
APPLICATION INFO.:	US 2006-386271	A1	20060321	(11)

	NUMBER	DATE

PRIORITY INFORMATION: US 2005-664381P 20050322 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AMGEN INC., MAIL STOP 28-2-C, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799, US
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2006:240521 USPATFULL Full-text
TITLE: Treatment of cancers expressing p95 erbb2
INVENTOR(S): Spector, Neil Lee, Durham, NC, UNITED STATES
Xia, Wenle, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006204966	A1	20060914	
APPLICATION INFO.:	US 2004-567012	A1	20040802	(10)
	WO 2004-US24888		20040802	
			20060201	PCT 371 date

TREATMENT w/ GW572016 (INSTANT CMPD.)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-491752P	20030801 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 1213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The truncated ErbB2 receptor (p95.sup.ErbB2) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with either EGFR or ErbB3. Consistent with p95.sup.ErbB2 heterodimerization with ErbB3, it is shown that heregulin (an ErbB3 ligand) stimulates p95.sup.ErbB2 phosphorylation in breast cancer cell lines. Described herein are methods of identifying patients suitable for treatment with a p95.sup.ErbB2 inhibitor, and methods of treating such patients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2006:222351 USPATFULL Full-text
TITLE: Anilinoquinazaolines as protein tyrosine kianse inhibitors
INVENTOR(S): Cockerill, George Stuart, Maulden, UNITED KINGDOM

Lackey, Karen Elizabeth, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20061896837	A1	20060824
	US 7189734	B2	20070313
APPLICATION INFO.:	US 2006-400284	A1	20060407 (11)

CMPDS & COMPOSITIONS

RELATED APPLN. INFO.: Division of Ser. No. US 2005-61578, filed on 18 Feb 2005, PENDING Division of Ser. No. US 2002-30527, filed on 9 Jan 2002, GRANTED, Pat. No. US 6933299

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-16213	19990709
	GB 1999-16218	19990709

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
LINE COUNT: 4471
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2006:209365 USPATFULL Full-text
TITLE: Use of EGFR tyrosinkinase inhibitors for treatment of chronic rhinosinusitis
INVENTOR(S): Jung, Birgit, Laupheim, GERMANY, FEDERAL REPUBLIC OF
Disse, Bernd, Mainz, GERMANY, FEDERAL REPUBLIC OF
Pohl, Gerald, Biberach, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006178364	A1	20060810
APPLICATION INFO.:	US 2006-275903	A1	20060202 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2005-102005005505 20050204	
	DE 2005-102005036216 20050802	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 838

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the use of selected EGFR kinase inhibitors, particularly selected quinazolines, quinolines and pyrimido-pyrimidines, for the treatment of nasal polyposis and chronic rhinosinusitis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2006:208454 USPATFULL Full-text

TITLE: Inhibiting HER2 shedding with matrix metalloprotease antagonists

INVENTOR(S): Carey, Kendall D., South San Francisco, CA, UNITED STATES
Schwall, Ralph, Pacifica, CA, UNITED STATES
Sliwkowski, Mark, San Carlos, CA, UNITED STATES
Schwall, Gail Colbern, Pacifica, CA, UNITED STATES
legal representative

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006177448	A1	20060810
APPLICATION INFO.:	US 2006-351811	A1	20060209 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-651348P	20050209 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 3198
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present application describes using antagonists of matrix metalloproteases (MMPs), especially of MMP-15, for inhibiting HER2 shedding.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2006:208384 USPATFULL Full-text

TITLE: Method for monitoring early treatment response

INVENTOR(S): Norfray, Joseph F., Glenview, IL, UNITED STATES

PATENT ASSIGNEE(S): RECEPTOMON, LLC, Glenview, IL, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006177378	A1	20060810
APPLICATION INFO.:	US 2005-193037	A1	20050729 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2005-53059, filed on 8 Feb 2005, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LEYDIG VOIT & MAYER, LTD, TWO PRUDENTIAL PLAZA, SUITE

4900, 180 NORTH STETSON AVENUE, CHICAGO, IL, 60601-6780, US
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 976
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a method for monitoring early treatment response of a cancer treatment comprising measuring by magnetic resonance spectroscopy (MRS), for example, proton MRS, the amount of Choline present in the tissue adjoining or surrounding the cancerous tissue before and after treatment; the treatment comprises administration of an angiogenesis inhibitor, for example, a VEGF inhibitor, whereby a decrease in the amount of Choline after treatment is indicative of a positive response. The decrease in the amount of Choline represents the decrease in the internal cell membrane as a result of down regulation of the organelles and their secretory granules and their transport vesicles. Disclosed also is a method for determining effectiveness of an angiogenesis inhibitor in the treatment of cancer. Also disclosed are methods of monitoring early treatment response in diseases where an angiogenesis effector, i.e., an inhibitor or promoter of angiogenesis, is employed. Also disclosed is a method for monitoring protein translation related to angiogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2006:208383 USPATFULL Full-text
TITLE: Method for monitoring early treatment response
INVENTOR(S): Norfray, Joseph F., Glenview, IL, UNITED STATES
PATENT ASSIGNEE(S): Receptomon, LLC., Glenview, IL, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006177377	A1	20060810	
APPLICATION INFO.:	US 2005-53059	A1	20050208	(11)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LEYDIG VOIT & MAYER, LTD, TWO PRUDENTIAL PLAZA, SUITE 4900, 180 NORTH STETSON AVENUE, CHICAGO, IL, 60601-6780, US
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 907
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a method for monitoring early treatment response of a cancer treatment comprising measuring by magnetic resonance spectroscopy (MRS), for example, proton MRS, the amount of Choline present in the tissue adjoining or surrounding the cancerous tissue before and after treatment; the treatment comprises administration of an angiogenesis inhibitor, for example, a VEGF inhibitor, whereby a decrease in the amount of Choline after treatment is indicative of a positive response. The decrease in the amount of Choline represents the decrease in the internal cell membrane as a result of down regulation of the organelles and their secretory granules and their transport vesicles. Disclosed also is a method for determining effectiveness of an angiogenesis inhibitor in the treatment of cancer. Also disclosed are methods of monitoring early treatment response in diseases where an

angiogenesis effector, i.e., an inhibitor or promoter of angiogenesis, is employed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2006:151492 USPATFULL Full-text
TITLE: Targeted therapy marker panels
INVENTOR(S): Bacus, Sarah S., Hinsdale, IL, UNITED STATES
Hill, Jason, Chicago, IL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006127928	A1	20060615	
APPLICATION INFO.:	US 2005-223700	A1	20050909	(11)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2004-635198P	20041210	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BRINKS HOFER GILSON & LIONE, P.O. BOX 10395, CHICAGO, IL, 60610, US
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Page(s)
LINE COUNT: 2055
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a panel of targeted therapy markers that can be used in assessing a particular subject's sensitivity to various therapeutic agents and cancer treatments as a means of prognosticating whether a treatment or use of a particular therapeutic agent will result in a clinically positive outcome. Cellular receptors, ligands to those receptors and molecules involved in the programmed cell death pathway are examples of targeted therapy markers that might be used in the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2006:131781 USPATFULL Full-text
TITLE: Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease
INVENTOR(S): Zeligs, Michael A., Boulder, CO, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006111423	A1	20060525	
APPLICATION INFO.:	US 2005-260543	A1	20051026	(11)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2004-622333P	20041026	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
NUMBER OF CLAIMS: 54

EXEMPLARY CLAIM: 1
LINE COUNT: 2738
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention includes compositions and methods for the treatment and prevention of conditions associated with Human Cytomegalovirus (HCMV) infection. HCMV-associated conditions include infections (active and latent), benign cell-proliferative conditions, pre-cancerous cell-proliferative conditions, and cancerous conditions. In particular, the present invention describes new therapeutic and preventative uses for 3,3'-diindolylmethane (DIM), or a DIM-related indole, in combination with an inhibitor of a membrane bound Growth Factor Receptor (GFR), to treat conditions associated with exposure to HCMV. In certain embodiments, the compositions of the invention can be used in combination with radiation therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2006:111124 USPATFULL Full-text
TITLE: Predictive markers in cancer therapy
INVENTOR(S): Bacus, Sarah S., Tuscon, AZ, UNITED STATES
Herrle, Myra R., Durham, NC, UNITED STATES
Kirk, L. Edward, Durham, NC, UNITED STATES
Spector, Neil L., Durham, NC, UNITED STATES
Stocum, Michael T., Durham, NC, UNITED STATES
Xia, Wenle, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006094068	A1	20060504	
APPLICATION INFO.:	US 2003-529922	A1	20030424	(10)
	WO 2003-US12739		20030424	
			20050330	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-389795P	20020619 (60)
	US 2002-432811P	20021211 (60)
	US 2002-432943P	20021211 (60)
	US 2003-451978P	20030305 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 1595
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Molecular markers useful in medicine response tests are provided, as an aid in determining whether an individual subject s tumor is responding to treatment with EGF and/or erbB2 inhibitors. Markers include phosphorylated ERK protein

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 17 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2006:99440 USPATFULL Full-text
TITLE: Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
INVENTOR(S): Geroni, Maria Cristina, Via Correggio 48, Milan, ITALY I-20149
Fowst, Camilla, Milan, ITALY
Cozzi, Paolo, Milan, ITALY

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006084612	A1	20060420	
APPLICATION INFO.:	US 2002-500606	A1	20021218	(10)
	WO 2002-EP13092		20021218	
			20050505	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2002-75052	20020102

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Peter I Bernstein, Scully Scott, Murphy & Presser, 400 Garden City Plaza, Suite 300, Garden City, NY, 11530, US
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 458
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides the combined use of acryloyl distamycin derivatives, in particular α-bromo- and α-chloro-acryloyl distamycin derivatives of formula (I), as set forth in the specification, and a protein kinase (serine/threonine and tyrosine kinases) inhibitor, in the treatment of tumors. Also provided is the use of the said combinations in the treatment or prevention of metastasis or in the treatment of tumors by inhibition of angiogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 18 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2006:41241 USPATFULL Full-text
TITLE: Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
INVENTOR(S): Jung, Birgit, Biberach, GERMANY, FEDERAL REPUBLIC OF
Himmelsbach, Frank, Mittelbiberach, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006035893	A1	20060216	
APPLICATION INFO.:	US 2005-189643	A1	20050726	(11)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2004-18808	20040807

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION,

900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 8735
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel pharmaceutical compositions comprising at least one EGFR kinase inhibitor and at least one additional active compound selected from beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK.sub.1 antagonists and endothelin-antagonists, processes for preparing the compositions and the use thereof as medicament in the treatment of respiratory or gastrointestinal complaints, as well as inflammatory diseases of the joints, the skin or the eyes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 19 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2005:318073 USPATFULL Full-text
TITLE: Antibody-drug conjugates and methods
INVENTOR(S): Ebens, Allen J. JR., San Carlos, CA, UNITED STATES
Jacobson, Frederic S., Berkeley, CA, UNITED STATES
Polakis, Paul, Burlingame, CA, UNITED STATES
Schwall, Ralph H., Pacifica, CA, UNITED STATES
Sliwkowski, Mark X., San Carlos, CA, UNITED STATES
Spencer, Susan D., Tiburon, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005276812	A1	20051215	
APPLICATION INFO.:	US 2005-141344	A1	20050531	(11)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2004-616098P	20041005	(60)
	US 2004-576517P	20040601	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US
NUMBER OF CLAIMS: 67
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 4618
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D).sub.p I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 20 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2005:313136 USPATFULL Full-text

TITLE: Method for treating abnormal cell growth
INVENTOR(S): Denis, Louis J., Pawcatuck, CT, UNITED STATES
Compton, Linda D., Richland, MI, UNITED STATES
PATENT ASSIGNEE(S): Pfizer Inc (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005272755	A1	20051208
APPLICATION INFO.:	US 2005-145097	A1	20050603 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-577268P	20040604 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612, US
NUMBER OF CLAIMS: 95
EXEMPLARY CLAIM: 1
LINE COUNT: 2926
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present Invention relates to a method of treating abnormal cell growth in a subject, comprising administering to said subject having abnormal cell growth: (a) a compound selected from the group consisting of a camptothecin, a camptothecin derivative, or a pharmaceutically acceptable salt, solvate or prodrug of said compounds; (b) a pyrimidine derivative or a pharmaceutically acceptable salt, solvate or prodrug of said pyrimidine derivative; and (c) an anti-tumor agent selected from the group consisting of antiproliferative agents, kinase inhibitors, angiogenesis inhibitors, growth factor inhibitors, cox-I inhibitors, cox-II inhibitors, mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, radiation, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, anti-androgens and combinations thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 21 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2005:275215 USPATFULL Full-text
TITLE: Novel medicament combinations for the treatment of respiratory diseases
INVENTOR(S): Konetzki, Ingo, Warthausen, GERMANY, FEDERAL REPUBLIC OF
Bouyssou, Thierry, Mietingen, GERMANY, FEDERAL REPUBLIC OF
Lustenberger, Philipp, Warthausen, GERMANY, FEDERAL REPUBLIC OF
Pieper, Michael P., Biberach, GERMANY, FEDERAL REPUBLIC OF
Schnapp, Andreas, Biberach, GERMANY, FEDERAL REPUBLIC OF
Hoenke, Christoph, Ingelheim, GERMANY, FEDERAL REPUBLIC OF
Pestel, Sabine, Attenweiler, GERMANY, FEDERAL REPUBLIC OF
Rudolf, Klaus, Warthausen, GERMANY, FEDERAL REPUBLIC OF
Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005239778	A1	20051027
APPLICATION INFO.:	US 2005-109094	A1	20050419 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2004-1020	20040422
	DE	20041103
	EP 2005-2496	20050207
	US 2004-578542P	20040610 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
NUMBER OF CLAIMS: 53
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 4182
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to new medicament combinations which contain in addition to one or more, preferably one, compound of general formula 1 ##STR1## wherein the groups R.sup.1, R.sup.2 and R.sup.3 may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 22 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2005:261902 USPATFULL Full-text
TITLE: Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
INVENTOR(S): Masferrer, Jaime L., Ballwin, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005227929	A1	20051013
APPLICATION INFO.:	US 2004-989192	A1	20041115 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-519701P	20031113 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Harness, Dickey & Pierce, P.L.C., Suite 400, 7700 Bonhomme, St. Louis, MO, 63105, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 12553
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treating or preventing neoplasia or a neoplasia-related disorder in a subject is provided, the method comprising administering to the subject an effective amount of a combination comprising a Cox-2 inhibitor and an antineoplastic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 23 OF 43 USPATFULL on STN NOT PFIZER ART

ACCESSION NUMBER: 2005:255665 USPATFULL Full-text
TITLE: Combinations of signal transduction inhibitors
INVENTOR(S): Eck, Stephen Louis, Ann Arbor, MI, UNITED STATES
Fry, David William, Ypsilanti, MI, UNITED STATES
Leopold, Judith Ann, Ann Arbor, MI, UNITED STATES
PATENT ASSIGNEE(S): PFIZER INC (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005222163	A1	20051006	
APPLICATION INFO.:	US 2005-95442	A1	20050330	(11)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2004-557623P	20040330	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AGOURON PHARMACEUTICALS, INC., 10777 SCIENCE CENTER DRIVE, SAN DIEGO, CA, 92121, US
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 3071
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for treating cancer comprising utilizing a combination of signal transduction inhibitors. More specifically, the present invention relates to combinations of so called cell cycle inhibitors with mitogen stimulated kinase signal transduction inhibitors, more specifically combinations of CDK inhibitors with mitogen stimulated kinase signal transduction inhibitors, more preferably MEK inhibitors. Other embodiments of the invention relate to additional combinations of the aforesaid combinations with standard anti-cancer agents such as cytotoxic agents, palliatives and antiangiogenics. Most specifically this invention relates to combinations of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl- pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one including salt forms, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor, in combination with one or more MEK inhibitors, most preferably N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-benzamide. The aforementioned combinations are useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 24 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2005:234149 USPATFULL Full-text
TITLE: Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors
INVENTOR(S): Pieper, Michael P., Biberach, GERMANY, FEDERAL REPUBLIC OF
Pohl, Gerald, Biberach, GERMANY, FEDERAL REPUBLIC OF
Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF
Jung, Birgit, Laupheim, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 2005203088 A1 20050915
APPLICATION INFO.: US 2005-28268 A1 20050103 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2004-10200400	20040109
	US 2004-557082P	20040326 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1783
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel drug compositions based on compounds of general formula 1 ##STR1## wherein X.sup.- and the groups A, B, R, R.sup.1, R.sup.2, R.sup.3, R.sup.3', R.sup.4 and R.sup.4' may have the meanings given in the claims and in the specification and EGFR kinase inhibitors, processes for preparing them and their use in the treatment of respiratory complaints.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

APPLICATION

L3 ANSWER 25 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2005:203315 USPATFULL Full-text
TITLE: Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
INVENTOR(S): Spector, Neil Lee, Durham, NC, UNITED STATES
Xia, Wenle, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005176740	A1	20050811	
APPLICATION INFO.:	US 2003-510542	A1	20030408	(10)
	WO 2003-US10747		20030408	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-370807P	20020408 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 3918
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a Raf and/or ras inhibitor to a mammal suffering from a cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 26 OF 43 USPATFULL on STN NOT PRIOR ART

ACCESSION NUMBER: 2005:190097 USPATFULL Full-text

TITLE: Pharmaceutical compositions containing anticholinergics and EGFR kinase inhibitors

INVENTOR(S): Meade, Christopher J. M., Maselheim, GERMANY, FEDERAL REPUBLIC OF
Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF
Pieper, Michael P., Biberach, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005165013	A1	20050728
APPLICATION INFO.:	US 2005-87153	A1	20050323 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2003-614382, filed on 7 Jul 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10230751	20020709
	US 2002-407746P	20020903 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1455
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel pharmaceutical compositions based on new anticholinergics and EGFR kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 27 OF 43 USPATFULL on STN NOT PRIOR ART

ACCESSION NUMBER: 2005:171858 USPATFULL Full-text

TITLE: Preventives and/or remedies for subjects with the expression or activation of her2 and/or egfr

INVENTOR(S): Suzuki, Tsuyoshi, Tokyo, JAPAN
Kitano, Yasunori, Tokyo, JAPAN
Yano, Shinji, Tokyo, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005148607	A1	20050707
APPLICATION INFO.:	US 2003-516360	A1	20030603 (10)
	WO 2003-JP6988		20030603

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2002-162130	20020603

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021, US
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1033
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A Her2 and/or EGFR inhibitor to be administered to a subject determined to show overexpression or activation of Her2 and/or EGFR as a result of a diagnosis of the subject for the expression or activity of Her2 and/or EGFR based on a test for detecting the expression or activity of Her2 and/or EGFR, and a pharmaceutical composition containing the inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 28 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2005:171813 USPATFULL Full-text
TITLE: Pharmaceutical compositions based on anticholinergics and additional active ingredients
INVENTOR(S): Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF
Pieper, Michael P., Biberach, GERMANY, FEDERAL REPUBLIC OF
Meade, Christopher John Montague, Maselheim, GERMANY, FEDERAL REPUBLIC OF
Reichl, Richard, Gau-Algesheim, GERMANY, FEDERAL REPUBLIC OF
Schmelzer, Christel, Ingelheim, GERMANY, FEDERAL REPUBLIC OF
Jung, Birgit, Laupheim, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. Kg, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005148562	A1	20050707
APPLICATION INFO.:	US 2004-6940	A1	20041208 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-776757, filed on 11 Feb 2004, PENDING Continuation of Ser. No. US 2001-86145, filed on 19 Oct 2001, ABANDONED Continuation-in-part of Ser. No. US 2004-775901, filed on 10 Feb 2004, PENDING Continuation of Ser. No. US 2001-27662, filed on 20 Dec 2001, ABANDONED Continuation-in-part of Ser. No. US 2003-613783, filed on 3 Jul 2003, PENDING Continuation of Ser. No. US 2002-93240, filed on 7 Mar 2002, ABANDONED Continuation-in-part of Ser. No. US 2004-763894, filed on 23 Jan 2004, PENDING Continuation of Ser. No. US 2003-419358, filed on 21 Apr 2003, GRANTED, Pat. No. US 6696042 Continuation of Ser. No. US 2002-92116, filed on 6 Mar 2002, GRANTED, Pat. No. US 6620438 Continuation-in-part of Ser. No. US 2003-413065, filed on 14 Apr 2003, ABANDONED Continuation of Ser. No. US 2002-100659, filed on 18 Mar 2002, GRANTED, Pat. No. US 6608054 Continuation-in-part of Ser. No. US 2004-824391, filed on 14 Apr 2004, PENDING Continuation of Ser. No. US 2001-7182, filed on 19 Oct 2001, ABANDONED Continuation-in-part of Ser. No. US 2003-360064, filed on 7 Feb 2003, PENDING

	NUMBER	DATE	
PRIORITY INFORMATION:	DE 2000-10054042	20001031	
	DE 2000-10062712	20001215	
	DE 2000-10063957	20001220	
	DE 2001-110772	20010307	
	DE 2001-111058	20010308	
	DE 2001-113366	20010320	
	DE 2001-138272	20010810	
	DE 2002-10206505	20020216	
	US 2000-257220P	20001221	(60)
	US 2000-253613P	20001128	(60)
	US 2000-257221P	20001221	(60)
	US 2001-281857P	20010405	(60)
	US 2001-281653P	20010405	(60)
	US 2001-281874P	20010405	(60)
	US 2001-314599P	20010824	(60)
	US 2000-253613P	20001128	(60)
	US 2002-369213P	20020401	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877-0368, US
NUMBER OF CLAIMS: 238
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 4621
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition comprising an anticholinergic and at least one additional active ingredient selected from among corticosteroids, dopamine agonistes, PDE-IV inhibitors, NK1-antagonists, endothelin antagonists, antihistamines, and EGFR-kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 29 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2005:165976 USPATFULL Full-text
TITLE: Anilinoquinazaolines as protein tyrosine kianse inhibitors
INVENTOR(S): Cockerill, George Stuart, Maulden, UNITED KINGDOM
Lackey, Karen Elizabeth, Durham, NC, UNITED STATES

CMPDS & COMPOSITIONS

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005143401	A1	20050630	
	US 7084147	B2	20060801	
APPLICATION INFO.:	US 2005-61578	A1	20050218	(11)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-303527, filed on 25 Nov 2002, GRANTED, Pat. No. US 6719339

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-16213	19990709
	GB 1999-16218	19990709

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
LINE COUNT: 4418
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 30 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2005:157855 USPATFULL Full-text
TITLE: Anti-IGFR antibody therapeutic combinations
INVENTOR(S): Wang, Yan, Scotch Plains, NJ, UNITED STATES
Pachter, Jonathan A., Chatham, NJ, UNITED STATES
Bishop, Walter Robert, Pompton Plains, NJ, UNITED STATES
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005136063	A1	20050623
APPLICATION INFO.:	US 2004-993395	A1	20041119 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-524732P	20031121 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 2883
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides combinations including a binding composition, such as an anti-IGFR1 antibody, in association with a chemotherapeutic agent. Methods for using the combinations to treat medical conditions, such as cancer, are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 31 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2005:152082 USPATFULL Full-text
TITLE: Heterocyclic compounds
INVENTOR(S): Carter, Malcolm Clive, Ware, UNITED KINGDOM
Cockerill, George Stuart, Bedford, UNITED KINGDOM
Guntrip, Stephen Barry, Hertford, UNITED KINGDOM
Lackey, Karen Elizabeth, Hillsborough, NC, UNITED STATES
Smith, Kathryn Jane, Hertfordshire, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20051309 96	A1	20050616
	US 7109333	B2	20060919
APPLICATION INFO.:	US 2005-50033	A1	20050203 (11)

method of inhibiting EGFR & c-erbB2

RELATED APPLN. INFO.: Continuation of Ser. No. US 2003-342810, filed on 15 Jan 2003, PENDING Continuation of Ser. No. US 2000-582746, filed on 30 Jun 2000, GRANTED, Pat. No. US 6727256 A 371 of International Ser. No. WO 1999-EP48, filed on 8 Jan 1999

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-569	19980112

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
LINE COUNT: 3538
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the preparation of a compound of formula (I) ##STR1## comprising the steps: (a) reacting a compound of formula (II) ##STR2## wherein L and L' are suitable leaving groups, with a compound of formula (III) UNH.sub.2 (III) to prepare a compound of formula (IV) ##STR3## and subsequently (b) substituting the group R.sup.1 by replacement of the leaving group L'.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

NIH PA/OA MAT

L3 ANSWER 32 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2005:138638 USPATFULL Full-text
TITLE: Dosing schedule for a novel anticancer agent
INVENTOR(S): Bhattacharya, Samit Kumar, Groton, CT, UNITED STATES
Connell, Richard Damian, East Lyme, CT, UNITED STATES
Jani, Jitesh, East Lyme, CT, UNITED STATES
Moyer, James Dale, East Lyme, CT, UNITED STATES
Noe, Dennis A., Madison, CT, UNITED STATES
Steyn, Stefanus Johannes, Oakdale, CT, UNITED STATES
PATENT ASSIGNEE(S): Pfizer Inc (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005119288	A1	20050602
APPLICATION INFO.:	US 2004-919831	A1	20040817 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-495919P	20030818 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612, US
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 1877

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to methods for the a method for treating overexpression of the erbB2 in a mammal in need of treatment by administering to the mammal a therapeutically effective amount of a first inhibitor of an erbB2 receptor and then, after an interval of less than 24 hours, administering to the mammal from one to six therapeutically effective amounts of the same or different inhibitor of the erbB2 receptor. The invention is also directed to a slow daily infusion of the erbB2 inhibitor. The overexpression of the erbB2 receptor can result in abnormal cell growth and lead to cancer. By the methods of the invention, the efficacy and safety of the inhibitors is increased. The invention is also directed to kits for facilitating the dose administration method of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

W/ IT PAPER HIT

L3 ANSWER 33 OF 43 USPATFULL on STN

ACCESSION NUMBER: 2004:292296 USPATFULL Full-text

TITLE: ErbB heterodimers as biomarkers

INVENTOR(S): Chan-Hui, Po-Ying, Oakland, CA, UNITED STATES
Dua, Rajiv, Manteca, CA, UNITED STATES
Mukherjee, Ali, Belmont, CA, UNITED STATES
Pidaparthi, Sailaja, Cupertino, CA, UNITED STATES
Salimi-Moosavi, Hossein, Sunnyvale, CA, UNITED STATES
Shi, Yining, San Jose, CA, UNITED STATES
Singh, Sharat, Los Altos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004229380	A1	20041118
APPLICATION INFO.:	US 2004-813412	A1	20040330 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-154042, filed on 21 May 2002, PENDING Continuation-in-part of Ser. No. US 2003-623057, filed on 17 Jul 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-494482P	20030811 (60)
	US 2003-508034P	20031001 (60)
	US 2003-512941P	20031020 (60)
	US 2003-523258P	20031118 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: ACLARA BIOSCIENCES, INC., 1288 PEAR AVENUE, MOUNTAIN VIEW, CA, 94043

NUMBER OF CLAIMS: 12

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 36 Drawing Page(s)

LINE COUNT: 2951

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to a new class of biomarker in patient samples comprising heterodimers of Her cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more heterodimers of ErbB, or Her, cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more heterodimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a

pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 34 OF 43 USPATFULL on STN NOT PRIOR ART

ACCESSION NUMBER:	2004:292210 USPATFULL Full-text
TITLE:	ErbB surface receptor complexes as biomarkers
INVENTOR(S):	Chan-Hui, Po-Ying, Oakland, CA, UNITED STATES Dua, Rajiv, Manteca, CA, UNITED STATES Mukherjee, Ali, Belmont, CA, UNITED STATES Pidaparthi, Sailaja, Cupertino, CA, UNITED STATES Salimi-Moosavi, Hossein, Sunnyvale, CA, UNITED STATES Shi, Yining, San Jose, CA, UNITED STATES Singh, Sharat, Los Altos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004229294	A1	20041118
APPLICATION INFO.:	US 2004-813417	A1	20040330 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-154042, filed on 21 May 2002, PENDING Continuation-in-part of Ser. No. US 2003-623057, filed on 17 Jul 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-459888P	20030401 (60)
	US 2003-494482P	20030811 (60)
	US 2003-508034P	20031001 (60)
	US 2003-512941P	20031020 (60)
	US 2003-523258P	20031118 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	ACLARA BIOSCIENCES, INC., 1288 PEAR AVENUE, MOUNTAIN VIEW, CA, 94043
NUMBER OF CLAIMS:	45
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	36 Drawing Page(s)
LINE COUNT:	3181

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of

receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 35 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2004:216030 USPATFULL Full-text
TITLE: Methods of treating cancer
INVENTOR(S): Potter, David A., Indianapolis, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004167139	A1	20040826
APPLICATION INFO.:	US 2003-629045	A1	20030728 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-399573P	20020726 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 1653
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for treating cancer are described herein. The methods include administering to an HIV-negative patient an m-calpain inhibitor such as ritonavir. Ritonavir or other m-calpain inhibitors can also be co-administered with other therapeutic agents such as a Cox-2 inhibitor, a taxane, or a proteasome inhibitor. Methods for determining whether a patient will respond to a particular method of treatment are also described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 36 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2004:165980 USPATFULL Full-text
TITLE: Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
INVENTOR(S): Masferrer, Jaime, Ballwin, MO, UNITED STATES
PATENT ASSIGNEE(S): Pharmacia Corporation, St. Louis, MO, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004127470	A1	20040701
APPLICATION INFO.:	US 2003-651916	A1	20030829 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-470951, filed on 22 Dec 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113786P	19981223 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Charles E. Dunlap, Nelson Mullins Riley & Scarborough, LLP, P.O. Box 11070, Columbia, SC, 29211-1070
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
LINE COUNT: 8937
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a novel method of preventing and/or treating neoplasia disorders in a subject that is in need of such prevention or treatment by administering to the subject at least one Cox-2 inhibitor in combination with an EGF receptor antagonist. Compositions, pharmaceutical compositions and kits are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 37 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2004:103738 USPATFULL Full-text
TITLE: Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
INVENTOR(S): Carter, Malcolm Clive, Ware, UNITED KINGDOM
Cockerill, George Stuart, Bedford, UNITED KINGDOM
Guntrip, Stephen Barry, Hertford, UNITED KINGDOM
Lackey, Karen Elizabeth, Hillsborough, NC, United States
Smith, Kathryn Jane, Bishop's Stortford, UNITED KINGDOM
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6727256	B1	20040427	
	WO 9935146		19990715	
APPLICATION INFO.:	US 2000-582746		20000630	(9)
	WO 1999-EP48		19990108	
			20000630	PCT 371 date

METHOD OF TREATING CANCER w/ INSTANT CMPD. (NOT COMBINATION)

ODP

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-569	19980112

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Rotman, Alan L.
ASSISTANT EXAMINER: Truong, Tamthom N.
LEGAL REPRESENTATIVE: Lemanowicz, John L.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3829
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted heteroaromatic compounds of formula (I), wherein X is N or CH; Y is CR.sup.1 and V is N; or Y is N and V is CR.sup.1; or Y is CR.sup.1 and V is CR.sup.2; or Y is CR.sup.2 and V is CR.sup.1; R.sup.1 represents a group CH.sub.3SO.sub.2CH.sub.2CH.sub.2NHCH.sub.2--Ar--, wherein Ar is selected from phenyl, furan, thiophene, pyrrole and thiazole, each of which may optionally be substituted by one or two halo, C.sub.1-4alkyl or C.sub.1-4alkoxy groups; R.sup.2 is selected from the group comprising hydrogen, halo, hydroxy, C.sub.1-4alkyl, C.sub.1-4alkoxy, C.sub.1-4alkylamino and di[C.sub.1-4alkyl]amino; U represents a phenyl, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl or 1H-

benzotriazolyl group, substituted by an R.sup.3 group and optionally substituted by at least one independently selected R.sup.4 group; R.sup.3 is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl, or R.sup.3 represents trihalomethylbenzyl or trihalomethylbenzyloxy; or R.sup.3 represents a group of formula (a) wherein each R.sup.5 is independently selected from halogen, C.sub.1-4alkyl, C.sub.1-4alkoxy; and n is 0 to 3; each R.sup.4 is independently hydroxy, halogen, C.sub.1-4alkyl, C.sub.2-4alkenyl, C.sub.2-4alkynyl, C.sub.1-4alkoxy, amino, C.sub.1-4alkylamino, di[C.sub.1-4alkyl]amino, C.sub.1-4alkylthio, C.sub.1-4alkylsulphinyl, C.sub.1-4alkylsulphonyl, C.sub.1-4alkylcarbonyl, carboxy, carbamoyl, C.sub.1-4alkoxycarbonyl, C.sub.1-4alkanoylamino, N-(C.sub.1- 4alkyl)carbamoyl, N,N-di(C.sub.1-4alkyl)carbamoyl, cyano, nitro and trifluoromethyl; and salts and solvates thereof, are disclosed, as are methods for their preparation, pharmaceutical compositions containing them and their use in medicine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 38 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2004:70718 USPATFULL Full-text
TITLE: Cancer treatment method
INVENTOR(S): Lackey, Karen Elizabeth, Durham, NC, UNITED STATES
Spector, Neil, Durham, NC, UNITED STATES
Wood III, Edgar Raymond, Durham, NC, UNITED STATES
Xia, Wenle, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20040053946	A1	20040318	
	US 7141576	B2	20061128	
APPLICATION INFO.:	US 2003-466290	A1	20030715	(10)
	WO -US201130			

INSTANT CMPD + PACLITAXEL FOR BREAST CANCER

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1780
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 39 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2004:64368 USPATFULL Full-text
TITLE: Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
INVENTOR(S): Meade, Christopher J. M., Bingen, GERMANY, FEDERAL REPUBLIC OF
Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF
Pieper, Michael P., Biberach, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF, 55216 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004048887	A1	20040311
APPLICATION INFO.:	US 2003-614382	A1	20030707 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10230751	20020709
	US 2002-407746P	20020903 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1486
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel pharmaceutical compositions based on new anticholinergics and EGFR kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 40 OF 43 USPATFULL on STN
ACCESSION NUMBER: 2003:319330 USPATFULL Full-text
TITLE: Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
INVENTOR(S): Singer, Thomas, Inzlingen, GERMANY, FEDERAL REPUBLIC OF
Platz, Stefan, Ummendorf, GERMANY, FEDERAL REPUBLIC OF
Colbatzky, Florian, Stafflangen, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & CO. KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003225079	A1	20031204
APPLICATION INFO.:	US 2003-431699	A1	20030508 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10221018	20020511
	US 2002-389815P	20020618 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 896
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention

and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 41 OF 43 USPATFULL on STN

ACCESSION NUMBER:	2003:251662 USPATFULL Full-text
TITLE:	Heterocyclic compounds
INVENTOR(S):	Carter, Malcolm Clive, Ware, UNITED KINGDOM Cockerill, George Stuart, Bedford, UNITED KINGDOM Guntrip, Stephen Barry, Hertford, UNITED KINGDOM Lackey, Karen Elizabeth, Hillsborough, NC, UNITED STATES Smith, Kathryn Jane, Bishop's Stortford, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003176451	A1	20030918
APPLICATION INFO.:	US 2003-342810	A1	20030115 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-582746, filed on 30 Jun 2000, PENDING A 371 of International Ser. No. WO 1999-EP48, filed on 8 Jan 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-569	19980112

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398
NUMBER OF CLAIMS:	6
EXEMPLARY CLAIM:	1
LINE COUNT:	3892

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the preparation of a compound of formula (I) ##STR1##

comprising the steps:

(a) reacting a compound of formula (II) ##STR2##

wherein L and L' are suitable leaving groups, with a compound of formula (III)

UNH.sub.2 (III)

to prepare a compound of formula (IV) ##STR3##

and subsequently (b) substituting the group R.sup.1 by replacement of the leaving group L'.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 42 OF 43 USPATFULL on STN

ACCESSION NUMBER:	2003:214419 USPATFULL Full-text
TITLE:	Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
INVENTOR(S):	Jung, Birgit, Laupheim, GERMANY, FEDERAL REPUBLIC OF Pueschner, Hubert, Biberach, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S):	Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003149062	A1	20030807	
APPLICATION INFO.:	US 2003-353616	A1	20030129	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10204462	20020205

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS:	8
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	2 Drawing Page(s)
LINE COUNT:	1686

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating inflammatory diseases of the airways or intestines which comprises administering substances selected from the group consisting of:

(a) quinazolines of general formula ##STR1##

wherein A, B, C, D, X, R.sup.a, R.sup.b, R.sup.c and n are as defined herein,

(b) the compounds

(1) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-dimethylamino-cyclohexyl)amino]-pyrimido[5,4-d]pyrimidine,

(2) 4-[(R)-(1-phenylethyl)amino]-6-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine, and

(3) 4-{[3-chloro-4-(3-fluoro-4-benzyloxy)-phenyl]amino}-6-(5-{[(2-methanesulphonyl-ethyl)amino]methyl}-furan-2-yl)quinazoline or

(d) the antibodies Cetuximab C225, Trastuzumab, ABX-EGF and Mab ICR-62, and

(f) EGFR-antisense.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 43 OF 43 USPATFULL on STN

ACCESSION NUMBER:	2002:266326 USPATFULL Full-text			
TITLE:	Heterocyclic compounds			
INVENTOR(S):	Carter, Malcolm Clive, Ware, UNITED KINGDOM Cockerill, George Stuart, Bedford, UNITED KINGDOM Guntrip, Stephen Barry, Hertford, UNITED KINGDOM Lackey, Karen Elizabeth, Hillsborough, NC, UNITED STATES Smith, Kathryn Jane, Bishop's Stortford, UNITED KINGDOM			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20021047205	A1	20021010	
	US 6713485	B2	20040330	
APPLICATION INFO.:	US 2002-71358	A1	20020208	(10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-582746, filed on 30 Jun 2000, PENDING			
	NUMBER	DATE		
PRIORITY INFORMATION:	GB 1998-569	19980112		
	WO 1999-EP48	19990108		
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, DURHAM, NC, 27709-3398			
NUMBER OF CLAIMS:	12			
EXEMPLARY CLAIM:	1			
LINE COUNT:	3860			

Treatment of cancer w/ claimed compound

O.D.P.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine. Specifically, the invention relates to quinazoline derivatives useful in treating disorders mediated by protein tyrosine kinase activity, in particular erbB-2 and/or EGFR activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> **d his**

(FILE 'HOME' ENTERED AT 16:16:10 ON 13 APR 2007)

FILE 'REGISTRY' ENTERED AT 16:16:38 ON 13 APR 2007
L1 STRUCTURE UPLOADED
L2 1 S L1 EXA FULL

FILE 'USPATFULL' ENTERED AT 16:17:17 ON 13 APR 2007
L3 43 S L2
L4 10 S L3 AND RAF

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	113.90	174.31

STN INTERNATIONAL LOGOFF AT 16:19:32 ON 13 APR 2007